NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Rockwell Medical, Inc. (RMTI) Stock Analysis

Rockwell Medical, Inc. (RMTI) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RMTI

$7.08

−$0.15 (−2.07%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RMTI with… →

RMTI Key Statistics

As of Oct 21, 2026
Trading
Open
$7.10
Previous Close
$7.23
Day's Range
7.05–7.50
52-Week Range
4.89–12.90
Volume
23.33K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$28.54M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
101.14
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.43
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.34
Financials (FY)
Revenue (FY)
$69.26M−31.76%
Net Income (FY)
−$5.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.03M
1-Year Return
−40.00%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
26.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RMTI closed at $7.08, −40.00% over 1 year.

Rockwell Medical, Inc. (RMTI) has a market capitalization of $28.54M.

In fiscal 2025, RMTI reported revenue of $69.26M.

RMTI Stock Return by Calendar Year

Rockwell Medical, Inc. (RMTI) 10-year return: what $10,000 became

1 year
$10,000 $6,000
−40.00%
5 years
$10,000 $1,129
−88.71%
10 years
$10,000 $106
−98.94%

If you had invested $10,000 in Rockwell Medical, Inc. (RMTI) 10 years ago, at the close on October 21, 2016, it would have been worth $106 at the close on October 21, 2026: −98.94% in total, −36.55% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.70%
2025−59.31%
2024+7.94%
2023+87.13%
2022−77.61%
2021−59.41%
2020−58.61%
2019+7.96%
2018−61.17%
2017−11.15%
2016 (partial year)−12.78%

As of October 21, 2026.

RMTI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$69.26M−$5.31M−7.7%
2024$101.49M−$480.00K−0.5%
2023$83.61M−$8.44M−10.1%
2022$72.81M−$18.68M−25.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$69.26M$11.70M−$4.69M−$5.31M−7.7%
2024$101.49M$17.48M$608.00K−$480.00K−0.5%
2023$83.61M$8.70M−$6.67M−$8.44M−10.1%
2022$72.81M$4.08M−$16.78M−$18.68M−25.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RMTI Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricRMTIDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.412.100.2x the median
Profit margin−7.33%−8.14%0.8 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Rockwell Medical, Inc. (RMTI) at $28.54M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 157 employees.

Over the past 52 weeks the price has ranged from $4.89 to $12.90. The most recent close on file for RMTI is $7.08, dated October 21, 2026. That is −$0.15 (−2.07%) against the previous close. The latest close sits 44.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $69.26M. That is −31.76% against the prior fiscal year, when revenue was $101.49M. The same year closed with a net loss of $5.31M. The reported profit margin is −7.33%. That is 0.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −1.34.

Across the 4 fiscal years on file, revenue moves from $72.81M in 2022 to $69.26M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 101.14. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.43. Measured against sales, the shares trade at 0.41 times revenue. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 1.63. Daily returns over the trailing 10 years annualize to a volatility of 81.97%. The trailing one-year total return is −40.00%. Across 10 years the annualized return works out at −36.55%.

Growth & Income

No dividend is on file for RMTI.

The strongest complete calendar year on file is 2023 at +87.13%; the weakest is 2022 at −77.61%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −14.70% year to date.

Peer Comparison

Rockwell Medical, Inc. (RMTI) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rockwell Medical, Inc. RMTI $28.54M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Rockwell Medical, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Rockwell Medical, Inc.

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Visit website →